Managing HIV

HIV therapy: managing resistance.

O the last years, a number of potent drugs have been developed that inhibit HIV-1 replication in vivo. Treatment regimes involving a combination of three or more different drugs can induce a decline in virus load by several orders of magnitude, as well as a significant rise in the CD4 cell count. The drugs currently in use mainly fall into two classes: reverse transcriptase inhibitors prevent i...

Managing HIV/AIDS in Malawi

The epidemic of HIV in Malawi started earlier than in most of southern Africa and at its peak 15% of all adults were infected with HIV. Malawi is a low-income country and the cost of putting all HIV-positive people in Malawi onto ART, expressed as a percentage of the gross domestic product, is the highest in the world. In spite of the scale of the epidemic and the cost of dealing with it, Malaw...

Diagnosing and managing diabetes in HIV-infected patients: current concepts.

Diabetes mellitus (DM) is a common condition with significant associated morbidity and mortality. DM diagnosis and management among human immunodeficiency virus (HIV)-infected patients is a particularly relevant topic as the HIV-infected population ages and more HIV-infected individuals live with chronic medical comorbidities. Although there is mixed evidence regarding HIV as an independent ris...

Managing drug interactions in HIV-infected adults with comorbid illness.

Managing dyslipidemia in HIV/AIDS patients: challenges and solutions

Human immunodeficiency virus (HIV) is a chronic disease associated with dyslipidemia and insulin resistance. In addition, the administration of combination antiretroviral therapy is associated with an increase in the incidence of metabolic risk factors (insulin resistance, lipoatrophy, dyslipidemia, and abnormalities of fat distribution in HIV patients). HIV dyslipidemia is a common problem, an...